Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Phase 1b, Single-ascending Dose and Optional re Dosing Study to Evaluate the Safety of VERVE-101 Administered to Patients With Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, and Uncontrolled Hypercholesterolemia

NCT05398029 is registered in ClinicalTrials.gov with Verve Therapeutics, Inc. as lead sponsor.

NCT NCT05398029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05398029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Phase 1b, Single-ascending Dose and Optional re Dosing Study to Evaluate the Safety of VERVE-101 Administered to Patients With Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, and Uncontrolled Hypercholesterolemia
Lead sponsor
Verve Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 5, 2022
Completion date
February 14, 2025
Enrollment
13 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, hypercholesterolemia